Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1

Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1

Glaucoma is a group of optic neuropathies characterized by the progressive degeneration of retinal ganglion cells (RGCs) as well as their axons leading to irreversible loss of sight. Medical management of the intraocular pressure (IOP) still represents the gold standard in glaucoma therapy, which on...

Full description

Bibliographic Details
Main Authors: Kristian Nzogang Fomo, Carsten Schmelter, Joshua Atta, Vanessa M. Beutgen, Rebecca Schwarz, Natarajan Perumal, Gokul Govind, Thomas Speck, Norbert Pfeiffer, Franz H. Grus
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Medicine
Subjects:
glaucoma
retina
autoimmunity
neuroprotection
synthetic CDR peptides
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.993351/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.993351/full

Similar Items